English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 856831      Online Users : 935
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/11552


    Title: Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer;a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
    Authors: Muro, K;Van Cutsem, E;Narita, Y;Pentheroudakis, G;Baba, E;Li, J;Ryu, MH;Zamaniah, WIW;Yong, WP;Yeh, KH;Kato, K;Lu, Z;Cho, BC;Nor, IM;Ng, M;Chen, LT;Nakajima, TE;Shitara, K;Kawakami, H;Tsushima, T;Yoshino, T;Lordick, F;Martinelli, E;Smyth, EC;Arnold, D;Minami, H;Tabernero, J;Douillard, JY
    Contributors: National Institute of Cancer Research
    Abstract: The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of gastric cancer was published in 2016, and covered the management and treatment of local, locoregional, locally advanced and metastatic disease. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and The Japanese Society of Medical Oncology (JSMO) to convene a special guidelines meeting immediately after the JSMO Annual Meeting in 2018. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic gastric cancer (mGC) in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with mGC representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the individual participating Asian countries.
    Date: 2019-01
    Relation: Annals of Oncology. 2019 Jan;30(1):19-33.
    Link to: http://dx.doi.org/10.1093/annonc/mdy502
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000459677700007
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85060128881
    Appears in Collections:[陳立宗] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PUB30475956.pdf617KbAdobe PDF250View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback